IMAX (IMAX) PT Lifted to $31.61 at Benchmark

Benchmark analyst Mike Hickey reiterated a Buy rating and raised his price target on IMAX Corporation (NYSE: IMAX) to $31.61 (from $30.54) following Q3 results.

Hickey commented, "We view the Company’s near term share price risk / reward profile balancing positive; as we believe the Company’s valuation has effectively discounted the weak current domestic box office, and suspect valuation consideration will shift to a looming CY’15 / CY’16 box office slate where we’re increasingly optimistic for strong box office performance. The announced CY’15 film slate includes: Seventh Son (February), Fast & Furious 7 (April), The Avengers: Age of Ultron (May), Tomorrowland (May), Jurassic World (June), Everest (September), Crimson Peak (October), Star Wars: Episode VII (December)."

For an analyst ratings summary and ratings history on IMAX Corporation click here. For more ratings news on IMAX Corporation click here.

Shares of IMAX Corporation closed at $28.55 yesterday.

You May Also Be Interested In

• Merck (MRK) PT Raised to $143 at Truist Securities
• Meta Platforms Inc. (META) PT Lowered to $575 at UBS, 'shares are offering a 3-to-1 skew'
• Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities